View:
Download DOC
Download PDF
Download XLS
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
LaSpaluto Michelle
(Last) (First) (Middle)
C/O CHIMERIX, INC.
2505 MERIDIAN PKWY, SUITE 100
(Street)
DURHAM NC 27713
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
12/01/2023 		3. Issuer Name and Ticker or Trading Symbol
CHIMERIX INC [ CMRX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 87,939(1) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (2) 01/27/2024 Common Stock 9,000 18.75 D
Stock Option (Right to Buy) (2) 12/03/2024 Common Stock 750 36.75 D
Stock Option (Right to Buy) (2) 01/27/2025 Common Stock 9,000 39.41 D
Stock Option (Right to Buy) (2) 07/31/2025 Common Stock 1,500 53.74 D
Stock Option (Right to Buy) (2) 07/31/2025 Common Stock 15,000 53.74 D
Stock Option (Right to Buy) (2) 01/07/2026 Common Stock 18,700 8.06 D
Stock Option (Right to Buy) (2) 12/14/2026 Common Stock 1,250 4.51 D
Stock Option (Right to Buy) (2) 01/24/2028 Common Stock 13,000 4.68 D
Stock Option (Right to Buy) (2) 01/22/2029 Common Stock 8,098 2.41 D
Stock Option (Right to Buy) (2) 09/25/2029 Common Stock 48,438 2.49 D
Stock Option (Right to Buy) 01/21/2020(3) 01/20/2030 Common Stock 62,067 2.08 D
Stock Option (Right to Buy) 01/22/2021(4) 01/21/2031 Common Stock 90,000 9.28 D
Stock Option (Right to Buy) 01/18/2022(4) 01/17/2032 Common Stock 95,000 5.62 D
Stock Option (Right to Buy) 01/17/2023(4) 01/16/2033 Common Stock 64,275 1.97 D
Explanation of Responses:
1. Amount includes 10,725 unvested shares pursuant to a restricted stock unit award issued on January 17, 2023.
2. Fully vested and exercisable.
3. 1/48th of the shares will vest each month over a four year period following the vesting commencement date. This stock option was previously exercised as to 25,933 shares.
4. 1/48th of the shares will vest each month over a four year period following the vesting commencement date.
Remarks:
/s/ Michael Alrutz, Attorney-in-Fact 12/04/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints
each of Michael Andriole and Michael Alrutz of Chimerix, Inc. (the "Company"),
signing individually, the undersigned's true and lawful attorney-in fact and
agent to:

(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of the Company, Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and

(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact
shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 4th day of December, 2023.

/s/ Michelle LaSpaluto
MICHELLE LASPALUTO